Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could the 'Love Hormone' help prevent dangerous low blood sugar in diabetes?

NCT ID NCT06881459

Knowledge-focused Sponsor: University Hospital, Gentofte, Copenhagen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether oxytocin, a natural hormone, can improve the body's ability to release glucagon during low blood sugar (hypoglycemia) in people with type 1 diabetes. Sixteen adults with type 1 diabetes received both oxytocin and a placebo on separate days to compare their glucagon responses. The goal was to understand if oxytocin could help protect against dangerously low blood sugar levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oxytocin
What this could lead to
If oxytocin boosts glucagon during hypoglycemia, it could point toward a new way to prevent dangerous low blood sugar in type 1 diabetes.
What could go wrong
This is a very small, early-stage study with only 16 participants. The effect may be small or not clinically meaningful, and oxytocin may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

16 people

The number who actually took part.

Started

Mar 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body mass index from 19 to 30 kg/m2 * T1D (diagnosed according to the criteria of the World Health Organization) with HbA1c \<69 mmol/mol (\<8.5%) * T1D duration of 3-30 years * C-peptide negative (stimulated C-peptide ≤ 100 pmol/l) * Treatment with a stable basal-bolus or insulin pump regimen for ≥3 months Exclusion Criteria: * Anaemia (haemoglobin below normal range) * Liver disease (alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>2 times normal values) or present hepatobiliary and/or gastrointestinal disorder(s) * Kidney disease (serum creatinine above normal range) * Late microvascular complications except mild non-proliferative retinopathy * Regular tobacco smoking or use of other nicotine-containing products * Long QTc on electrocardiogram (ECG) at screening (≥0.45 seconds) * Pituitary gland disease * Treatment with any glucose-lowering drugs besides insulin * Any ongoing medication or physical or psychological condition that the investigator feels would interfere with trial participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes

Contacts and locations

Locations

  • Center for Clinical Metabolic Research, Gentofte Hospital

    Hellerup, 2900, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.